Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmaceuticals Inc. reports news on its specialty pharmaceutical portfolio and North American commercial operations. The company's updates center on GRAFAPEX (treosulfan) for Injection in the United States, financial results, and product-level trends across therapeutic areas that include hematology and hematology-oncology, rheumatology, allergy, and dermatology.
Medexus news also covers capital allocation and capital structure actions, including credit facilities, warrant expirations, and normal course issuer bid activity, along with shareholder meeting results, conference calls, and management participation in investor conferences.
Medexus (OTCQX: MEDXF) reported fiscal Q2 2026 results for the period ended September 30, 2025, driven by early commercial traction for GRAFAPEX (treosulfan). Net revenue was $24.7M for the quarter and $49.4M year-to-date, down 6.1% and 7.8% YoY respectively. Medexus recorded product-level GRAFAPEX net revenue of $3.1M (Q2) and $6.2M (YTD) against ~$3.0M and $6.0M of launch investments. Adjusted EBITDA was $4.4M (Q2) and $7.8M (YTD). Available liquidity was $9.4M at Sept 30, 2025, after $16.6M principal repayments since March 31, 2025.
Medexus Pharmaceuticals (OTCQX: MEDXF) will hold a conference call at 8:00 AM ET on Thursday, November 13, 2025 to discuss results for the second fiscal quarter ended September 30, 2025. The company expects to file its financial statements and MD&A after markets close on November 12, 2025.
Live dial-in numbers are provided for Canadian/U.S. and international callers with Access Code 988000. A live webcast will be available on the Investors section of Medexus's website and a replay will be available by phone and online through Friday, November 13, 2026.
Medexus Pharmaceuticals (OTCQX:MEDXF) successfully conducted its virtual annual shareholders meeting, where all proposed directors were elected for the upcoming term. The shareholders demonstrated strong support for the board nominees, with approval ratings ranging from 92.19% to 96.45%.
Additionally, shareholders overwhelmingly approved the appointment of PricewaterhouseCoopers LLP as the company's auditors with 99.51% of votes in favor. The voting results will be filed with Canadian securities regulatory authorities.
Medexus Pharmaceuticals (OTCQX:MEDXF) reported fiscal Q1 2026 results, featuring $24.6 million in net revenue and $0.5 million in net income. The quarter highlighted the successful launch of GRAFAPEX, generating $3.0 million in product-level revenue. The company achieved $3.4 million in Adjusted EBITDA and $3.9 million in operating cash flow.
GRAFAPEX's launch shows promising momentum with 9 large commercial payers covering approximately 48 million patient lives, and 36 transplant centers representing 24% of total allo-HSCT procedures in the US already ordering the product. The company expects GRAFAPEX to be cash flow accretive by fiscal Q3 2026 and projects annual product-level revenue to exceed $100 million within five years.
The company reduced its total debt by $15.5 million to $22.0 million as of June 30, 2025, while maintaining $9.3 million in available liquidity.
Medexus Pharmaceuticals (OTCQX:MEDXF) has scheduled its first fiscal quarter 2026 earnings conference call for August 13, 2025, at 8:00 am Eastern Time. The company will release its financial results and MD&A for the quarter ended June 30, 2025, after market close on August 12, 2025.
Additionally, Medexus management will participate in two upcoming investor conferences: Cannacord Genuity's 45th Annual Growth Conference in Boston (August 12-14, 2025) and the LD Micro Main Event in San Diego (October 19-21, 2025).
Medexus Pharmaceuticals (OTCQX: MEDXF) has secured CMS approval for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX (treosulfan) for Injection in fiscal year 2026. Starting October 1, 2025, eligible procedures will receive up to $21,411 in additional reimbursement through the NTAP program.
The approval marks a significant milestone, as GRAFAPEX was one of only five approvals out of 13 applications under the traditional pathway. Since its US commercial launch in February 2025, GRAFAPEX has gained positive formulary inclusion from 9 large commercial payers covering approximately 48 million patient lives, and 14 healthcare institutions. Additionally, 37 transplant centers have ordered GRAFAPEX, demonstrating strong initial institutional uptake.
Medexus Pharmaceuticals (OTCQX:MEDXF) reported strong fiscal year 2025 results, with revenue of $108.3 million and record net income of $2.2 million. The company achieved record Adjusted EBITDA of $20.2 million, up 3.6% year-over-year.
A key highlight was the early commercial launch of GRAFAPEX in February 2025, following FDA approval in January. Initial market response has been positive, with 34 transplant centers ordering the product and four large commercial payers covering approximately 34 million patient lives making positive formulary inclusion determinations. Medexus expects GRAFAPEX annual revenue to exceed $100 million within five years post-launch.
The company's available liquidity increased to $24.0 million as of March 31, 2025, up from $5.3 million the previous year, primarily due to a public offering of Common Shares in January 2025.
Medexus Pharmaceuticals (MEDXF) has secured a significant reimbursement agreement with Quebec's Public Prescription Drug Insurance Plan (RAMQ) for Trecondyv® (treosulfan for injection). This achievement marks public reimbursement coverage in Canada's three most populous provinces, reaching approximately 75% of the Canadian population.
The company is actively pursuing reimbursement approvals from remaining provincial, territorial, and federal government organizations to expand Trecondyv® accessibility through public drug plans. This development also signals positive prospects for both Trecondyv® in Canada and GRAFAPEX™ (treosulfan) for Injection in the US market.
Medexus Pharmaceuticals (MEDXF) reports positive initial progress on the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States since its February 24 launch. The company has already sold the product to 16 unique institutions, with several procedures completed using commercially available GRAFAPEX™.
Key highlights include:
- Expected annual product-level Adjusted Gross Margin of approximately 80%, compared to recent portfolio-wide margins of 56.3% (Q3 2025) and 59.5% (Q2 2025)
- Projected annual product-level revenue of at least US$100 million within five years after launch
- Inclusion in NCCN Clinical Practice Guidelines in Oncology on February 28
- 34 presentations and abstracts relating to treosulfan presented at the 2025 EBMT Annual Meeting
The company expects GRAFAPEX™ to be accretive to quarterly operating cash flows by fiscal Q4 2026 and is monitoring potential impacts of new U.S. tariffs on imports.